RxDoctor Payments Data

Mojun Zhu, MD

Medical Oncology · Rochester, MNNPI 1376923581

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.

$162in general payments, 2019–2025

Across 2 payments — averaging $80.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$93
  • AstraZeneca$68
$1,054,868in research payments, 2019–2025

Across 33 payments — averaging $31,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$314K
  • AstraZeneca$305K
  • Pfizer$164K
  • E.r. Squibb & Sons, L.L.C.$113K
  • AbbVie$66K
  • Beone Medicines USA, Inc.$61K
  • plus $32K from 1 others

What the payments were for

  • Food & beverage$9358%
  • Education$6842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc1$93
AstraZeneca1$68

How this compares

$162 in reported general payments places this provider in the 30th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,269,010
Medicare patients
477
Services billed
73,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone55$357
Prochlorperazine Maleate23$310
Ondansetron Hcl23$164
LoperamideLoperamide Hcl32$134
Oxycodone Hcl11$58

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →